Drug Trial Radar · NCT05021120
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Oct 12, 2021
Primary completion
Oct 1, 2024
Study completion Apr 1, 2025
Sponsor
- Lead sponsor
- Akesobio Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK127 in combination with AK104.
Conditions
- Advanced or Metastatic Solid Tumours
Interventions
AK127Drug
Subjects will receive AK127 by intravenous administration
AK104Drug
After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Nature of Adverse Events (AEs)Time frame: From the time of informed consent signed through to 90 days after end of treatment
- Number of participants with a Dose Limiting Toxicity (DLT)Time frame: Within the first six weeks of treatment
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Ashford Cancer Centre Research
Adelaide, Australia
Austin Health
Melbourne, Australia
Monash Health
Melbourne, Australia
Southside Cancer Care Centre
Sydney, Australia
The Kinghorn Cancer Centre, St Vincents Hospital Sydney
Sydney, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.